ReviewClinical reviews in allergy & immunology2010
High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases.
Review in Clinical reviews in allergy & immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 56 citations in OpenAlex.
- Autoimmune Bullous Diseases: Therapeutic Update.Drugs · 2026Review
- Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice.British journal of pharmacology · 2020Article
- Proteases in Pemphigoid Diseases.Frontiers in immunology · 2019Review
- Current Clinical Trials in Pemphigus and Pemphigoid.Frontiers in immunology · 2019Review
- Editorial: Autoantibodies.Frontiers in immunology · 2019Article
- Long-Term Follow-Up after Intravenous Immunoglobulin Therapy in Patients with Severe Ocular Mucous Membrane Pemphigoid Unresponsive to Conventional Therapy.Journal of ophthalmology · 2018Article
- Epidermolysis Bullosa Acquisita: The 2019 Update.Frontiers in medicine · 2018Review
- Anti-idiotypic Antibodies against BP-IgG Prevent Type XVII Collagen Depletion.Frontiers in immunology · 2017Article
- Optimal Synthetic Glycosylation of a Therapeutic Antibody.Angewandte Chemie (International ed. in English) · 2016Article
- Optimal Synthetic Glycosylation of a Therapeutic Antibody.Angewandte Chemie (Weinheim an der Bergstrasse, Germany) · 2016Article
- A novel combination approach of human polyclonal IVIG and antibiotics against multidrug-resistant Gram-positive bacteria.Infection and drug resistance · 2016Article
- Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita.The Journal of investigative dermatology · 2015Article
- Intravenous immunoglobulin in pediatrics: A review.Medical journal, Armed Forces India · 2014Article
- Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2013Article
- Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.ISRN dermatology · 2013Article
- The future of autoimmunity.Clinical reviews in allergy & immunology · 2012Article
- Cutting-edge issues in organ-specific autoimmunity.Clinical reviews in allergy & immunology · 2011Article
- The diagnosis and treatment of autoimmune blistering skin diseases.Deutsches Arzteblatt international · 2011Review
- [Optimizing therapy in patients with severe autoimmune blistering skin diseases].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment of autoimmune bullous skin diseases can often be challenging and primarily consists of systemic corticosteroids and a variety of immunosuppressants. Current treatment strategies are effective in most cases but hampered by the side effects of long-term immunosuppressive treatment. Intravenous immunoglobulin (IVIG) is one potential promising therapy for patients with autoimmune bullous skin diseases, and evidence of its effectiveness and safety is increasing. A number of autoimmune bullous skin diseases have been identified in which IVIG treatment may be beneficial. However, experience with IVIG in patients with autoimmune skin blistering disease is limited, where it is recommended for patients not responding to conventional therapy. The mode of action of IVIG in autoimmune diseases, including bullous diseases is far from being completely understood. We here summarize the clinical evidence supporting the notion, that IVIG is a promising therapeutic agent for the treatment of patients with autoimmune bullous skin disease. In addition, we review the proposed modes of action. In the future, randomized controlled trials are necessary to better determine the efficacy and adverse effects of IVIG in the treatment of autoimmune bullous skin diseases. In addition, insights into IVIG's mode of action might enable us to develop novel therapeutics to overcome the current shortage of IVIG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.